Changes in androgens during treatment with four low-dose contractptives

Coenen, C; Thomas, Chris M.G.; Borm, George F.; Hollanders, J.M.G.; Rolland, R.

doi:10.1016/0010-7824(96)00006-6

Cited by 132 publications

(72 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore only women who had not used hormonal contraception for at least 3 months were included in the study and there was a 3-cycle run-in period with COC use alone prior to the DHEA/placebo treatment period. The observed qualitative changes of the (precursor) androgens and SHBG after COC use alone are in agreement with previous studies [1,2,[17][18][19][20][21], but the quantitative suppression of total T and free T by 62% and 86%, respectively is more pronounced than reported in the literature previously (mean of 31% and 61%, respectively) [1]. Importantly, all COC users experienced a decrease of their total and free T.…”

Section: Discussionsupporting

confidence: 92%

“…A small but significant lowering of albumin by COC use only has been observed in some [2,31] but not all [32] earlier studies. In the current study neither the COC use only nor the addition of DHEA affected albumin levels.…”

Section: Amusa I Endo Tables 18 Julymentioning

confidence: 99%

“…In addition, the estrogenic component of COCs, ethinylestradiol (EE), stimulates hepatic sex hormone-binding globulin (SHBG) production considerably in a dose-dependent manner [1]. Because SHBG binds and inactivates T, there is further suppression of the free T concentrations (up to 61%) and the free androgen or T index (FAI or FTI), a measure of bioavailable T, is significantly reduced [1,2].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Restoring testosterone levels by adding dehydroepiandrosterone to a drospirenone containing combined oral contraceptive: I. Endocrine effects

et al. 2015

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 92%

Section: Amusa I Endo Tables 18 Julymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Restoring testosterone levels by adding dehydroepiandrosterone to a drospirenone containing combined oral contraceptive: I. Endocrine effects

et al. 2015

View full text Add to dashboard Cite

“…Accordingly, ethinyloestradiol in contraceptive doses also reduced DHEA-S levels by 20-40% (27,28). However, oestrogen replacement failed to change DHEA-S levels in subjects with impaired ovarian function such as Turner patients (9) or postmenopausal women (20,29).…”

Section: Discussionmentioning

confidence: 99%

Hormonal changes during the first year of oestrogen treatment in constitutionally tall girls

Wajs-Kuto

Beeck²,

Rooman³

et al. 1999

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Oestrogens are used to inhibit growth in girls with constitutionally tall stature. We studied the changes in different hormones that accompany such therapy. Subjects and methods:In this longitudinal study we examined the levels of total insulin-like growth factor-I (IGF-I), free thyroxine (FT 4 ), thyrotrophin (TSH), testosterone, dehydroepiandrosterone sulphate (DHEA-S), cortisol and prolactin in two groups of girls receiving ethinyloestradiol at a dose of either 0.1 mg daily (group A, n = 22) or 0.2 mg daily (group B, n = 36). Hormonal measurements were performed at start of therapy and after 3, 6 and 12 months. Results: In both groups the levels of IGF-I, testosterone and DHEA-S were reduced while the concentrations of cortisol and prolactin were increased. The pituitary-thyroid axis was not significantly affected by this therapy. The girls receiving 0.2 mg ethinyloestradiol daily had lower IGF-I levels after 12 months of therapy and had higher serum prolactin concentrations than the girls treated with 0.1 mg daily. The reduction in predicted height and the advancement in bone age were similar in both groups. Conclusions: Therapy with pharmacological doses of ethinyloestradiol changes the levels of several hormones including IGF-I, testosterone, DHEA-S, prolactin and cortisol but the role of the respective changes in the inhibition of growth is not clear. The suppression of DHEA-S levels by 40% suggests that the ovaries contribute significantly to the production of this hormone in pubertal girls.

show abstract

“…[5][6][7][8][9] Another well-documented effect of OC therapy is a significant increase (>150%) in sex hormone-binding globulin (SHBG) levels. 7,[10][11][12] Thus, addition of an androgen such as MT to an OC formulation should both decrease the circulating levels of SHBG and provide androgens to compensate for the diminished androgen status of women receiving OC therapy who have subnormal or lower limits of normal levels of androgens. [13][14][15] In summary, the endogenous formation and serum levels of bioavailable sex hormones in women taking OCs are suppressed directly by central negative feedback and indirectly by affecting the levels of SHBG.…”

Section: Effects Of An Oral Contraceptive Combination With or Withoutmentioning

confidence: 99%

Oral Contraceptives Use by Young Women Reduces Peak Bone Mass

2000

View full text Add to dashboard Cite

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate FUNDING NUMBERSDAMD17-98-1-8514 PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)Bowman Gray School of Medicine Winston-Salem, North Carolina 27157register@wfubmc.edu SUPPLEMENTARY NOTESReport contains color graphics. 12a. DISTRIBUTION / AVAILABILITY STATEMENTApproved for public release; Distribution unlimited 12b. DISTRIBUTION CODE ABSTRACT (Maximum 200 Words)The purpose of the proposed studies was to determine the role that hypoandrogenemia plays in the effects of oral contraceptives (OC) on bone metabolism and peak bone mass (PBM) in young female rats. Intact, adolescent/young adult Sprague-Dawley rats were treated with 1) placebo, 2) OC therapy, 3) OC supplemented with an androgen (methyltestosterone), or 4) anti-androgen therapy (bicalutamide) to determine the potential role that suppression of androgens plays on bone metabolism, bone architecture, and the attainment of PBM. Our specific aims were to determine: 1.If oral contraceptive steroid (OC) use leads to decreased peak bone mass in young intact female rats. Findings: OC use decreased the peak bone mass of young intact female rats. 2.If the addition of a non-aromatizable androgenic steroid to OCs prevents the detrimental effects of OC use on peak bone mass. Findings: The non-aromatizable androgenic steroid did not prevent the adverse effects of OCs to the growing skeleton of young rats at the dose used. 3.If the effects of OC use on peak bone mass are equivalent to the effects caused by anti-androgen use. Findings: The anti-androgen used did not mimic the adverse effect of OCs on the growing skeleton of young rats.

show abstract

Changes in androgens during treatment with four low-dose contractptives

Cited by 132 publications

References 17 publications

Restoring testosterone levels by adding dehydroepiandrosterone to a drospirenone containing combined oral contraceptive: I. Endocrine effects

Restoring testosterone levels by adding dehydroepiandrosterone to a drospirenone containing combined oral contraceptive: I. Endocrine effects

Hormonal changes during the first year of oestrogen treatment in constitutionally tall girls

Oral Contraceptives Use by Young Women Reduces Peak Bone Mass

Contact Info

Product

Resources

About